CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab

CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab

Here, we report on a novel bispecific antibody-derivative, designated RTX-CD47, with unique capacity for CD20-directed inhibition of CD47-SIRPα “don't eat me” signaling. RTX-CD47 comprises a CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv. Si...

Full description

Bibliographic Details
Main Authors: Peter E. van Bommel, Yuan He, Ilona Schepel, Mark A. J. M. Hendriks, Valerie R. Wiersma, Robert J. van Ginkel, Tom van Meerten, Emanuele Ammatuna, Gerwin Huls, Douwe F. Samplonius, Wijnand Helfrich, Edwin Bremer
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:OncoImmunology
Subjects:
bispecific antibody
cd47
phagocytosis
rituximab
sirpα
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1386361

Internet

http://dx.doi.org/10.1080/2162402X.2017.1386361

Similar Items